Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
07:05am, Monday, 01'st Mar 2021
~ Six patient procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with full enrollment of first cohort expected mid-2021 ~
uniQure to Participate in Multiple Upcoming Industry Conferences in March
07:05am, Friday, 26'th Feb 2021
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with seve
UniQure (QURE) to Report Q4 Results: Wall Street Expects Earnings Growth
01:39pm, Monday, 22'nd Feb 2021
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UniQure's stock rallies 7% on positive safety data for Huntington's disease treatment
02:03pm, Monday, 08'th Feb 2021
Shares of UniQure gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical trial for its experimen
~ No Significant Safety Concerns Observed ~
uniQure to Participate in Multiple Upcoming Industry Conferences in February
07:05am, Monday, 01'st Feb 2021
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with seve
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
11:27pm, Monday, 04'th Jan 2021
New York, New York--(Newsfile Corp. - January 4, 2021) - Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are ad
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
04:43pm, Saturday, 26'th Dec 2020
New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
04:20am, Wednesday, 23'rd Dec 2020
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact
Why uniQure Stock Is Tanking Today
01:31pm, Monday, 21'st Dec 2020
A clinical hold is weighing on the biotech's shares today.
5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential
08:15am, Monday, 21'st Dec 2020
After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
UniQure Plunges As FDA Slaps Clinical Hold On Hemophilia B Gene Therapy Study On Possible Liver Cancer Link
07:55am, Monday, 21'st Dec 2020
Uniqure NV (NASDAQ: QURE) shares are moving sharply to the downside after the gene therapy company announced a setback to its clinical study. What Happened: Lexington, Massachusetts-based uniQure sai
uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
07:05am, Monday, 21'st Dec 2020
Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET
4 Biotechs That Could Be Potential Acquisition Targets in 2021
10:32am, Thursday, 17'th Dec 2020
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~
